Highly phagocytic, CD4hi, CD14hi and CD16hi antigen-presenting cells modulated by tumour-conditioned media retain the capacity to mature and induce TH1 T-cell proliferation

Molecular Immunology

Volumn 43, Issue 13, 2006, Pages 2070-2082

  Metharom, P ^a   Velten, F W ^a   Goerdt, S ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

DC; Dendritic cells; Phenotypic analysis; T cell proliferation; Tumour conditioned medium

Indexed keywords

ALLOANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD4 ANTIGEN; CYTOKINE; DEXTRAN; INTERLEUKIN 10; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN PRESENTING CELL; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL SECRETION; COLON CARCINOMA; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MELANOMA; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TUMOR CELL LINE; UPREGULATION; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; NEOPLASM;

ANIMALIA;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, CD4; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; CYTOKINES; HUMANS; NEOPLASMS; RECEPTORS, IGG; TH1 CELLS;

EID: 33645872977     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2005.12.008     Document Type: Article

References (60)

1. Almand B., Clark J., Nikitina E., van Beynen J., English N., Knight S., Carbone D., and Gabrilovich D. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166 (2001) 678-689
2. Becker Y. Dendritic cell activity against primary tumors: an overview. In Vivo 7 (1993) 187-191
3. Bell D., Chomarat P., Broyles D., Netto G., Harb G., Lebecque S., Valladeau J., Davoust J., Palucka K., and Banchereau J. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190 (1999) 1417-1426
4. Bernhard H., Lohmann M., Batten W., Metzger J., Lohr H., Peschel C., zum Buschenfelde K., and Rose-John S. The gp130-stimulating designer cytokine hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into functional dendritic cells. Exp. Hematol. 28 (2000) 365-372
5. Bhowmick N., Chytil A., Plieth D., Gorska A., Dumont N., Shappell S., Washington M., Neilson E., and Moses H. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303 (2004) 848-851
6. Chomarat P., Banchereau J., Davoust J., and Palucka A. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol. 1 (2000) 510-514
7. Chomarat P., Dantin C., Bennett L., Banchereau J., and Palucka A. TNF skews monocyte differentiation from macrophages to dendritic cells. J. Immunol. 171 (2003) 2262-2269
8. Costello R., Gastaut J., and Olive D. Tumor escape from immune surveillance. Arch. Immunol. Ther. Exp. (Warsz) 47 (1999) 83-88
9. Duperrier K., Velten F., Bohlender J., Demory A., Metharom P., and Goerdt S. Immunosuppressive agents mediate reduced allostimulatory properties of myeloid-derived dendritic cells despite induction of divergent molecular phenotypes. Mol. Immunol. 42 (2005) 1531-1540
10. Figdor C., de Vries I., Lesterhuis W., and Memoli V. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10 (2004) 475-480
11. Gabrilovich D., Nadaf S., Corak J., Berzofsky J., and Carbone D. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell. Immunol. 170 (1996) 111-119
12. Ijland S., Jager M., Heijdra B., Westphal J., and Peek R. Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res. 9 (1999) 445-450
13. Inoshima N., Nakanishi Y., Minami T., Izumi M., Takayama K., Yoshino I., and Hara N. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non small cell lung cancer. Clin. Cancer Res. 8 (2002) 3480-3486
14. Iwamoto M., Shinohara H., Miyamoto A., Okuzawa M., Mabuchi H., Nohara T., Gon G., Toyoda M., and Tanigawa N. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int. J. Cancer 104 (2003) 92-97
15. Jonuleit H., Kuhn U., Muller G., Steinbrink K., Paragnik L., Schmitt E., Knop J., and Enk A. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27 (1997) 3135-3142
16. Jonuleit H., Schmitt E., Steinbrink K., and Enk A. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol. 22 (2001) 394-400
17. Kiertscher S., Luo J., Dubinett S., and Roth M. Tumors promote altered maturation and early apoptosis of monocyte-drived dendritic cells. J. Immunol. 164 (2000) 1269-1276
18. Kitamura H., Kamon H., Sawa S., Park S., Katunuma N., Ishihara K., Murakami M., and Hirano T. IL-6-STAT3 controls intracellular MHC class II ab dimer level through cathepsin S activity in dendritic cells. Immunity 23 (2005) 491-502
19. Kovalovich K., Li W., DeAngelis R., Greenbaum G., Ciliberto G., and Taub R. Interleukins-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL. J. Biol. Chem. 276 (2001) 26605-26613
20. Kronin V., Vermec D., and Shortman K. Does the IL-2 receptor alpha chain induced on dendritic cells have a biological function?. Int. Immunol. 10 (1998) 237-240
21. Kubo T., Hatton R., Oliver J., Liu X., Elson C., and Weaver C. Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J. Immunol. 173 (2004) 7249-7258
22. Kusmartsev S., Nefedova Y., Yoder D., and Gabrilovich D. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172 (2004) 989-999
23. Kusmartsev S., Nefedova Y., Yoder D., and Gabrilovich D. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species (Erratum). J. Immunol. 172 (2004) 4647
24. Kuwana M. Induction of anergic and regulatory T cells by plasmacytoid dendritic cells and other dendritic cell subsets. Hum. Immunol. 63 (2002) 1156-1163
25. Lotz M., Jirik F., Kabouridis P., Tsoukas C., Hirano T., Kishimoto T., and Carson D. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J. Exp. Med. 167 (1988) 1253-1258
26. Manavalan J., Rossi P., Vlad G., Piazza F., Yarilina A., Cortesini R., Mancini D., and Suciu-Foca N. High expression of ILT2 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl. Immunol. 11 (2003) 245-258
27. McBride J., Jung T., de Vries J., and Aversa G. IL-10 alters DC function via modulation of cell surface molecules resulting in impaired T-cell response. Cell. Immunol. 215 (2002) 162-172
28. 2 production by monocytes. Br. J. Cancer 79 (1999) 119-130
29. Menetrier-Caux C., Thomachot M., Alberti L., Montamain G., and Blay J. IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Res. 61 (2001) 3096-3104
30. Mitani H., Katayama N., Araki H., Ohishi K., Kobayashi K., Suzki H., Nishii K., Masuya M., Yasukawa K., Minami N., and Shiku H. Activity of interleukin 6 in the differentiation of monocytes to macrophages and dendritic cells. Br. J. Haematol. 109 (2000) 288-295
31. low regulatory dendritic cells. J. Immunol. 172 (2004) 7341-7349
32. Mouawad R., Rixe O., Meric J., Khayat D., and Soubrane C. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cell. Mol. Ther. 7 (2002) 151-156
33. Netea M., van der Graaf C., van der Meer J., and Kullberg B. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J. Leukoc. Biol. 75 (2004) 749-755
34. Ninomiya T., Akbar S., Masumoto T., Horiike N., and Onji M. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J. Hepatol. 31 (1999) 323-331
35. Park S., Nakagawa T., Kitamura H., Atsumi T., Kamon H., Sawa S., Kaminura D., Ueda N., Iwakura Y., Ishihara K., Murakami M., and Hirano T. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol. 173 (2004) 3844-3854
36. Pawelec G. Immunotherapy and immunoselection-tumour escape as the final hurdle. FEBS Lett. 567 (2004) 63-66
37. Ratta M., Fagnoni F., Curti A., Vescovini R., Sansoni P., and Oliviero B. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100 (2002) 230-237
38. Re F., and Strominger J. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem. 276 (2001) 37692-37699
39. Roncarolo M., Bacchetta R., Bordignon C., Narula S., and Levings M. Type 1 T regulatory cells. Immunol. Rev. 182 (2001) 68-79
40. Salgado R., Vermeulen P., Benoy I., Weytjens R., Huget P., Marck E., and Kirix L. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br. J. Cancer 80 (1999) 892-897
41. Satyamoorthy K., DeJesus E., Linnenbach A., Kraj B., Kornreich D., Rendle S., Elder D., and Herlyn M. Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res. 7 (1997) S35-S42
42. Schwaab T., Schned A., Heaney J., Cole B., Atzpodien J., Wittke F., and Ernstoff M. In vivo description of dendritic cells in human renal cell carcinoma. J. Urol. 162 (1999) 567-573
43. Seymour J., Talpaz M., Hagemeister F., Cabanillas F., and Kurzrock R. Clinical correlates of elevated serum levels of interleukin-6 in patients with untreated Hodgkin's Disease. Am. J. Med. 102 (1997) 21-28
44. Shurin M., Yurkovetsky Z., Tourkova I., Balkir L., and Shurin G. Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int. J. Cancer 101 (2002) 61-68
45. Sombroek C., Stam A., Masterson A., Lougheed S., Schakel M., Meijer C., Pinedo H., van den Eertwegh A., Scheper R., and de Gruijl T. Prostanoids play a major role in the primar tumor-induced inhibition of dendritic cells differentiation. J. Immunol. 168 (2002) 4333-4343
46. Speiser D., Pittet M., Valori D., Dunber R., Rimodi D., Liénard D., MacDonald H., Cerottini J., Cerundolo V., and Romero P. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J. Exp. Med. 190 (1999) 775-782
47. Sun Z., Klein A., Radaeve S., Hong F., El-Assal O., and Pan H. In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology 125 (2003) 202-215
48. Tobin S., Douville K., Benbow U., Brinckerhoff C., Memoli V., and Arrick B. Consequences of altered TGF-β expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects. Oncogene 21 (2002) 108-118
49. Torre-Amione G., Beauchamp R., Koeppen H., Park B., Schreiber H., Moses H., and Rowley D. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. PNAS 87 (1990) 1490
50. Tourkova I., Shurin G., Chatta G., Perez L., Finke J., Whiteside T., Ferrone S., and Shurin M. Restoration by IL-15 of MHC class I antigen-processing machinery in human dendritc cells inhibited by tumour-derived gangliosides. J. Immunol. 175 (2005) 3045-3052
51. Toyonaga T., Nakano K., Nagano M., Zhao G., Yamaguchi K., Kuroki S., Eguchi T., Chijiiwa K., Tsuneyoshi M., and Tanaka M. Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett. 201 (2003) 107-116
52. Uyttenhove C., Coulie P., and Van Snick J. T cell growth and differentiation induced by interleukin-HP1/IL-6, the murine hybridoma/plasmacytoma growth factor. J. Exp. Med. 167 (1988) 1417-1427
53. Velten F., Duperrier K., Bohlender J., Metharom P., and Goerdt S. A gene signature of inhibitory MHC receptors identifies a BDCA3+ subset of IL-10-induced dendritic cells with reduced allostimulatory capacity in vitro. Eur. J. Immunol. 34 (2004) 2800-2811
54. Vermi W., Bonecchi R., Facchetti F., Bianchi D., Sozzani S., Festa S., Berenzi A., Cella M., and Colonna M. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritiec cells in primary cutaneous melanomas. J. Pathol. 200 (2003) 255-268
55. Waller E., Rosenthal H., Jones T., Peel J., Lonial S., Langston A., Redei I., Jurickova I., and Boyer M. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 97 (2001) 2948-2956
56. Waller E., Rosenthal H., Jones T., Peel J., Lonial S., Langston A., Redei I., Jurickova I., and Boyer M. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation (Erratum). Blood 98 (2005) 1677
57. Wang Q., Redovan C., Tubbs R., Olencki T., Klein E., Kudoh S., Finke J., and Bukowski R. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int. J. Cancer 61 (1995) 780-785
58. Wei L., Kuo M., Chen C., Chou C., Lai K., Lee C., and Hsieh C. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22 (2003) 1517-1527
59. Whiteside T., Stanson J., Shurin M., and Ferrone S. Antigen-processing machinery in human dendritic cells: Up-regulation by maturation and down-regulation by tumor cells. J. Immunol. 173 (2004) 1526-1534
60. Yoshizawa K., Naruto M., and Ida N. Injection time of interleukin-6 determines fatal outcome in experimental endotoxin shock. J. Interferon Cytokine Res. 16 (1996) 995-1000